Senator Bill Cassidy Criticizes HHS’s Shift in Vaccine Funding

Senator Bill Cassidy from Louisiana has expressed his disapproval regarding the Department of Health and Human Services (HHS) decision to redirect funds originally allocated for mRNA vaccine development. He believes that this shift aligns with former President Donald Trump’s goal of restoring the nation’s health.

The HHS Secretary stated, “We reviewed science, listened to experts, and acted accordingly.” According to a press statement from HHS, Robert F. Kennedy Jr. indicated that the Biomedical Advanced Research and Development Authority (BARDA) has halted its investments in mRNA vaccines, citing their ineffectiveness against upper respiratory infections like COVID-19 and the flu. Instead, they will allocate funds to a more reliable, broader vaccine platform that remains effective against mutated viruses.

Cassidy voiced his concerns about this decision, lamenting the cancellation of important projects. “It’s unfortunate that the secretary has put a stop to five billion jobs and wasted previous investments,” he commented. He also pointed out that expertise from China plays a crucial role in combating diseases like cancer and infections. Trump, he believes, aims to restore health in America and ultimately make the country great again.

The HHS clarified that while some existing contracts with companies like Arcturus will continue to receive support, no new mRNA ventures will be initiated. They have also instructed the Global Health Investment Corporation (GHIC), which manages BARDA, to maintain focus on existing investments.

Additionally, Cassidy’s criticism comes at a time when he is seeking re-election in 2026, amid competition from fellow Republicans eyeing Senate seats.

Back in February 2021, Cassidy notably voted to convict Trump following the events of January 6 at the U.S. Capitol, although the Senate vote fell short of the necessary majority for conviction.